Answers are grounded in this paper and cite their sources.
Research demonstrates that immune changes influence multiple sclerosis progression, suggesting new treatment pathways.
The H3.3low/EREhigh signature may not only explain the common skewed myelopoiesis in MS and post-COVID-19 conditions, but also provide a mechanistic link between infection and the innate immune reprogramming that drives MS progression. This offers a novel therapeutic insight for MS.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: